该研究由生产艾可拓的武田制药赞助。
The study was funded by Takeda Pharmaceuticals, which manufactures Actos.
艾可拓和亚莫利作用非常不同。艾可拓增强胰岛素敏感性。亚莫利刺激胰腺分泌胰岛素。
Actos and Amaryl work very differently. Actos makes the body more sensitive to insulin. Amaryl stimulates the pancreas to release more insulin.
艾可拓背着一个“黑锅”，警告这种药物可能引起心衰，但是到目前为止并未发现它增加心脏事件的危险性。
Actos carries a "black box" warning that the drug may trigger heart failure, but it has not been linked to any increased risk of heart attack.
Nissen说这项研究设计并不是旨在确定艾可拓是否确实降低心血管事件和中风的危险性，但他认为这种益处“接下来一定会带来更好的临床效益。”
Nissen says that the study was not designed to determine whether Actos actually cuts the risk of heart attacks and stroke, but he thinks it "will translate into clinical benefits down the road."
Nissen说这项研究设计并不是旨在确定艾可拓是否确实降低心血管事件和中风的危险性，但他认为这种益处“接下来一定会带来更好的临床效益。”
Nissen says that the study was not designed to determine whether Actos actually cuts the risk of heart attacks and stroke, but he thinks it "will translate into clinical benefits down the road."
应用推荐